MRD Response-adapted Allo-HSCT for Adverse-risk AML

This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.

Trial Details

NCT ID
NCT06301425
Phase
NA
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Intervention group
  • Control group
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Newly diagnosed AML;
  • Categorized into adverse-risk group according to ELN 2022 criteria;
  • 16-65 years of age at the time of diagnosis;
  • achieving CR after 1 or 2 courses of induction chemotherapies;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →